Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.

ABSTRACT:

Background

Levodopa-carbidopa intestinal gel (LCIG) is administered directly to the small intestine of patients with advanced Parkinson's disease (APD) to help maintain stable plasma levodopa levels.

Objective

The objective of this study was to investigate the effect of LCIG in reducing polypharmacy for the treatment of APD.

Methods

The COmedication Study assessing Mono- and cOmbination therapy with levodopa-carbidopa inteStinal gel (COSMOS) is a large, real-world, multinational observational study investigating comedication use with LCIG. All enrolled patients had used LCIG for ≥12 months and data were collected cross-sectionally (study visit) and retrospectively. The primary endpoint was the percentage of patients using LCIG as monotherapy (without add-on PD medicat

SUBMITTER: Fasano A 

PROVIDER: S-EPMC8453961 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature